Why did the CSL share price beat the ASX 200 on Wednesday?

Why did CSL shares outperform the benchmark ASX 200 index today?

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares rose 0.68% to $261.76 while the ASX 200 Index fell 0.20% today 
  • The global biotech's share price was supported by an uptick across the ASX 200 Health Care index 
  • Both Citi and Morgan Stanley believe that CSL shares are grossly undervalued at current levels 

The CSL Limited (ASX: CSL) share price finished higher today despite the S&P/ASX 200 Index (ASX: XJO) closing in the red.

At Wednesday’s market close, the global biotech’s shares rose 0.68% to $261.76 apiece.

By comparison, the benchmark ASX 200 index shed 0.20% to 6,508.5 points.

What drove CSL shares higher today?

With no announcements from the company, investors rallied the CSL share price throughout the day.

A rebound on the S&P/ASX 200 Health Care Index (ASX: XHJ) helped support this move after falling almost 2% in the past week.

Investors appeared to have focused on performing sectors as most of the market headed for another day of losses.

The recent volatility across the ASX has been impacted by the talk surrounding more possible rate hikes to combat inflation.

During the March quarter, inflation rose by 5.1% which was the highest level seen in many years.

And with the United States possibly facing a recession in 2023, this has sent investors packing.

Nonetheless, CSL shares continue to trade at attractive levels with many brokers believing its undervalued.

In particular, Citi remains positive on CSL shares due to its high-growth and defensive qualities.

As such, the broker has a buy rating and price target of $335. This represents an upside of roughly 28% based on the current share price.

On the other hand, Morgan Stanley has an overweight rating with a price target of $302 per share. While not as bullish as Citi, this still implies an upside of about 15% from where CSL trades today.

CSL share price summary

Since the start of 2022, the CSL share price has fallen by roughly 10%.

However, when looking further back, its shares are down almost 13% in the past 12 months.

CSL is the third largest company on the ASX with a market capitalisation of approximately $126.17 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Up 50% in a month: Why all these fundies predict more greatness for the Telix Pharmaceuticals share price

Several professional fund managers say the Telix Pharmaceuticals share price is on a growth trajectory. Here's why.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Dividend Investing

Medibank shares are currently trading on a 4% dividend yield. How does this compare to NIB?

Medibank vs. NIB... who wins when it comes to dividends?

Read more »

Two healthcare workers, a male doctor in the background with a woman in scrubs in the foreground,, smile towards the camera against a plain backdrop.
Broker Notes

5 reasons to buy this ASX healthcare share: Goldman Sachs

This could be the healthcare share to buy right now...

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Up 8% in July, is there more upside in the CSL share price this earnings season?

CSL is forecast to benefit from an improved outlook for plasma collections.

Read more »

A dollar sign embedded in ice, indicating a share price freeze or trading halt
Healthcare Shares

Why is the Mesoblast share price on ice today?

Mesoblast is another share placed on pause today.

Read more »

Woman holding out her hand, symbolising a trading halt.
Healthcare Shares

Medical Developments share price halted amid ‘significant near-term opportunities’

The company seeks to raise additional capital.

Read more »

A woman stretches her arms into the sky as she rises above the crowd.
Healthcare Shares

Up 22% in a month, can the Imugene share price extend its rally?

Imugene extends its gains today.

Read more »

Doctor reading a file
Healthcare Shares

What’s been impacting the Ramsay Health share price this week?

The hospital operator has decided to go its own way...

Read more »